Current opinion in neurology
-
Curr. Opin. Neurol. · Feb 2010
ReviewReperfusion for acute ischemic stroke: arterial revascularization and collateral therapeutics.
Reperfusion of the ischemic territory forms the basis of most acute stroke treatments. This overview of the literature relating to reperfusion in acute ischemic stroke published within the last year provides a snapshot of a rapidly evolving aspect of cerebrovascular disease. ⋯ These timely findings illustrate the essential role of reperfusion in acute stroke, delineating aspects of arterial revascularization and collateral therapeutics to be refined in coming years.
-
Curr. Opin. Neurol. · Feb 2010
ReviewCraniectomy for acute ischemic stroke: how to apply the data to the bedside.
Malignant hemispheric infarction is associated with a high mortality rate, approximately 80%, as a result of the development of intracranial pressure gradients, brain tissue shift, and herniation. By allowing the brain to swell outwards and equalizing pressure gradients, decompressive craniectomy appears to significantly reduce the mortality to approximately 20%. This review takes a comprehensive look at the evidence highlighting the benefits and limits of decompressive craniectomy in malignant cerebral infarction. ⋯ Early decompressive hemicraniectomy (
60 years old) and perhaps, when delayed beyond 48 h. -
Tissue-type plasminogen activator is the only pharmacological treatment approved for acute ischemic strokes but is administered to less than 5% of the patients. Excessive prehospital and in-hospital delays and lack of stroke center coverage are major issues that negatively impact stroke care. New strategies are being developed and evaluated to increase the number of tissue-type plasminogen activator-treated patients. ⋯ The shortening of prehospital delays requires education of patients and health professionals and optimization of transport strategies. Future developments may include video conferencing offering telestroke expertise, strategies (i.e. therapeutic interventions) that might help to treat acute stroke patients with tissue-type plasminogen activator, and prehospital selection of candidates for endovascular therapies.
-
Curr. Opin. Neurol. · Dec 2009
ReviewManagement of cervical spondylotic myelopathy with insights from metabolic imaging of the spinal cord and brain.
Cervical spondylotic myelopathy (CSM) is a potentially debilitating disorder primarily related to spinal cord injury caused by degenerative changes of the spine. As the population continues to age and live longer, it is likely that this disorder will be encountered with increasing frequency. ⋯ CSM is a complex disorder whose incidence is likely to increase in coming years. Prospective, randomized studies are required to help establish the optimal treatment paradigm. Recent advances such as novel neuroimaging techniques and the continued development of neural repair strategies to treat the secondary biological injury associated with this disorder are likely to play key roles in the future management of CSM.